|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2006-8-14
|
|
pubmed:abstractText |
A strategy of systematically targeting more rigid analogues of the known MCH R1 receptor antagonist, SB-568849, serendipitously uncovered a binding mode accessible to N-aryl-phthalimide ligands. Optimisation to improve the stability of this compound class led to the discovery of novel N-aryl-quinazolinones, benzotriazinones and thienopyrimidinones as selective ligands with good affinity for human melanin-concentrating hormone receptor 1.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:Al-BarazanjiKamalK,
pubmed-author:BatesonJohnJ,
pubmed-author:HamprechtDieterD,
pubmed-author:HaynesAndreaA,
pubmed-author:HervieuGuillaume JGJ,
pubmed-author:JeffreyPhillipP,
pubmed-author:JohnsonChristopher NCN,
pubmed-author:MuirAlison IAI,
pubmed-author:O'HanlonPeter JPJ,
pubmed-author:StempGeoffreyG,
pubmed-author:StevensAlex JAJ,
pubmed-author:ThewlisKevinK,
pubmed-author:WinbornKim YKY,
pubmed-author:WittyDavid RDR
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4872-8
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849.
|
|
pubmed:affiliation |
GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK. david.witty@gsk.com
|
|
pubmed:publicationType |
Journal Article
|
